The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.

The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.

Date of Patent:
Jul. 29, 2025

Filed:

Jun. 11, 2020
Applicants:

Umc Utrecht Holding B.v., Utrecht, NL;

Sentryx B.v., Austerlitz, NL;

Bo-ip B.v., Zeist, NL;

Inventors:

Susanna Piluso, Utrecht, NL;

Jasper Gerard Steverink, Austerlitz, NL;

Joannes Jacobus Verlaan, Utrecht, NL;

Bas Jeroen Oosterman, Austerlitz, NL;

Assignees:

UMC Utrecht Holding B.V., Utrecht, NL;

SentryX B.V., Utrecht, NL;

BO-IP B.V., Zeist, NL;

Attorney:
Primary Examiner:
Int. Cl.
CPC ...
A61K 47/69 (2017.01); A61K 31/445 (2006.01); A61K 45/06 (2006.01); A61K 47/61 (2017.01);
U.S. Cl.
CPC ...
A61K 47/6903 (2017.08); A61K 31/445 (2013.01); A61K 45/06 (2013.01); A61K 47/61 (2017.08); A61K 47/6915 (2017.08); A61K 47/6951 (2017.08);
Abstract

A hydrogel for in-vivo release of medication includes at least one medication, where the hydrogel includes (i) a protein-based biopolymer functionalized with a functionalisation agent that is able to form guest-host interactions with oxidized β-cyclodextrin, preferably a primary aminoalkylphenol, more preferably gelatin functionalized with tyramine (GTA) and (ii) oxidized β-cyclodextrin (oβ-CD), where the hydrogel is cross-linked via exposure to visible light in presence of a biocompatible photoinitiator, resulting in a degree of swelling in the range of 2-20 calculated as (swollen weight−dry weight)/dry weight. It further relates to a method for its preparation, as well as to a medication for treatment of musculoskeletal disorders, preferably for treatment of infection, inflammation, malignant processes, growth disorders, degenerative disorders or treatment of pain arising from (surgical treatment of) these disorders.


Find Patent Forward Citations

Loading…